1. A polypeptide construct comprising:
a first portion comprising the second constant domain (C_{H2}) and/or third constant domain (C_{H3}) of an antibody heavy chain, and
a second portion comprising at least two TGF-β superfamily receptor ectodomains (TβSR-ED) linked in tandem,
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion.

2. A polypeptide construct comprising:
a first portion comprising the second constant domain (CH2) and/or third constant domain (CH3) of an antibody heavy chain, and
a second portion comprising at least one TGF-β superfamily receptor ectodomains (TβSR-ED),
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion,
and further wherein the first portion does not further comprise an antibody that binds to an antigen that is PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.

3. A polypeptide construct comprising:
a first portion comprising the second constant domain (C_{H2}) and/or third constant domain (C_{H3}) of an antibody heavy chain, and
a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED),
wherein the N-terminus of the second portion is directly fused to the C-terminus of the first portion.

4. A polypeptide construct comprising
a first portion comprising the second constant domain (C_{H2}) and/or third constant domain (C_{H3}) of an antibody heavy chain, and
a second portion comprising at least one TGF-β superfamily receptor ectodomain (TβSR-ED),
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and wherein the polypeptide construct neutralizes TGF-β with at least 100-fold more potency than the TβSR-ED alone.

5. The polypeptide construct of claims **2-4**, wherein the second portion comprises one TβSR-ED.

6. The polypeptide construct of claim **5**, wherein the second portion comprises two TβSR-EDs.

7. The polypeptide construct according to claims **1-6**, wherein the TβSR-ED is a TGF-β receptor type II ectodomain (TβR-II-ED).

8. The polypeptide construct of claims **1-6**, wherein the TβSR-ED comprises a sequence selected from the group consisting of SEQ ID NO:35, SEQ ID NO:69, SEQ ID NO:75, SEQ ID NO:81, and a sequence substantially identical thereto.

9. The polypeptide construct of claims **1-8**, wherein the second portion comprises a sequence selected from the group consisting of SEQ ID NO:43-SEQ ID NO:51, SEQ ID NO:61-SEQ ID NO:68, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:79, SEQ ID NO:80, SEQ ID NO:85, SEQ ID NO:86, SEQ ID NO:88, and a sequence substantially identical thereto.

10. The polypeptide construct of any one of claims **1-8**, wherein the first portion further comprises a C_{H1}, a C_{H1} and V_H, or C_{H1} and scFv.

11. The polypeptide construct of any one of claims **1-10**, wherein the antibody heavy chain is of human origin.

12. The polypeptide construct of any one of claims **1-11**, wherein the antibody heavy chain is selected from the group consisting of a human IgG1, IgG2, IgG3, or IgG4 heavy chain.

13. The polypeptide construct of any one of claims **1-12**, wherein the antibody heavy chain is a human IgG1.

14. The polypeptide construct of claim **4**, wherein the polypeptide construct shows longer in vivo half-life compared to the half-life of the second portion alone.

15. The polypeptide construct of any one of claims **1-14**, wherein the polypeptide construct is a single chain polypeptide.

16. The polypeptide construct of any one of claims **1-15**, wherein the polypeptide construct forms a dimeric polypeptide.

17. The polypeptide construct of claims **1-16**, wherein the polypeptide construct is heterodimeric.

18. A polypeptide construct selected from the group consisting of any one of SEQ ID NO:91 to SEQ ID NO:120, and a sequence substantially identical thereto.

19. A polypeptide construct according to claims **1-16**, wherein the construct comprises an antibody, antigen binding fragment thereof, or a targeting moiety.

20. A polypeptide construct according to claim **19**, comprising the antibody, antigen binding fragment, or targeting moiety at the N-terminus of the first portion.

21. A polypeptide construct according to claim **19**, wherein the antigen binding fragment may be selected from the group consisting of a Fv, scFv, Fab, or sdAb.

22. A polypeptide construct according to claim **19**, wherein the antigen binding fragment binds to an antigen that is not PD-L1, EGFR1, Her-2, CD4, CD6, CD20, CD25, MUC-1, IL-2, IL-6, or CTLA-4.

23. A polypeptide construct according to claim **19**, wherein the antibody is selected from the group consisting of Cetuximab, Avastin, Herceptin, Synagis, and FC5.

24. A polypeptide construct according to claim **23**, wherein the antibody is Cetuximab.

25. A polypeptide construct according to claim **19**, wherein the targeting moiety comprises a poly-aspartate sequence motif for bone targeting.

26. A polypeptide construct according to claim **25**, wherein the targeting moiety comprises D10.

27. A polypeptide construct according to any preceding claim wherein the construct is a dimeric polypeptide.

28. A polypeptide construct according to claim **27**, wherein the dimeric polypeptide comprises:
a first single chain polypeptide comprising a first portion comprising the second constant domain (C_{H2}) and third constant domain (C_{H3}) of an antibody heavy chain, and a heavy chain variable region of a given antibody;
a second portion comprising one or more TGF-β superfamily receptor ectodomains (TβSR-ED),
wherein the N-terminus of the second portion is linked to the C-terminus of the first portion, and
a second single chain polypeptide comprising a first portion comprising the second constant domain (C_{H2}) and third constant domain (C_{H3}) of an antibody heavy chain, and a light chain variable region of said given antibody;
a second portion comprising one or more TGF-β superfamily receptor ectodomain (TβSR-ED) which is the same or different from the ectodomain(s) in the first